WORK Medical (WOK) Technology Group announced that its subsidiary, Neologics Bioscience, entered into a key service agreement. his move is not only a significant milestone in WORK Medical’s global expansion strategy and business diversification initiatives, but also signals a pivotal shift in the company’s strategy-moving efficiently from capital injection to research and development execution. Pursuant to the Agreement, Neologics agrees to serve as an independent contractor to provide specified testing services for GemPharmatech. These services will cover the entire process from material preparation, serum titer analysis, hybridoma fusion and screening, antibody sequencing and production, to in vitro validation for several purified recombinant antibodies, as requested by GemPharmatech during the term of the Agreement. As consideration, GemPharmatech has agreed to pay $114,000 in total to Neologisc for the services rendered under the work orders associated with the Agreement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WOK:
- WORK Medical Technology Group LTD Implements Share Consolidation to Meet Nasdaq Requirements
- WORK Medical Technology Group Announces Extraordinary General Meeting for Share Capital Changes
- WORK Medical to make $1M equity investment in Neologics Bioscience
- Work Medical Technology Group Ltd trading halted, news pending
- Upcoming Stock Splits This Week (October 20 to October 24) – Stay Invested
